Intravenous immunoglobulin treatment for @entity6715 and XXXX : a prospective noncomparative study showing no benefit on mortality or progression.

@entity1 @entity8 @entity137 @entity6715 @entity12 @entity1011 @entity204
BACKGROUND: It has been proposed that Fas- @entity12 interaction was responsible for the apoptosis of epidermal cells in @entity6715 ( @entity6715 ) and @entity137 ( @entity137 ) and that high doses of intravenous immunoglobulin (IVIG) could help @entity1 by blocking the apoptosis. OBJECTIVE: To study the effects of IVIG on @entity6715 and @entity137 . DESIGN: Prospective open trial. SETTING: Referral center of a university hospital. @entity1 : Thirty-four consecutive @entity1 admitted for @entity6715 (n = 9), @entity6715 (n = 5), or @entity137 (n = 20) a mean of 4.3 days after onset. INTERVENTION: A dose of 2 g/kg of IVIG was administered within 2 days (half doses or full doses over a longer period for @entity1 with low @entity1011 clearance). MAIN OUTCOME MEASURES: Detached plus detachable proportions of the total body surface area measured before and after treatment and predicted @entity204 rate estimated on admission with a validated prognostic score. RESULTS: Epidermal detachment involved a mean +/- SD 19% +/- 16% of the total body surface area on admission and 32% +/- 26% after IVIG treatment (progression in 22 of 34 cases, including most @entity1 referred early). The prognostic score predicted 8.2 @entity204 (24%); 11 were observed (32%; 95% confidence interval, 17%-51%). Most @entity204 occurred in elderly @entity1 who had initially @entity8 . CONCLUSIONS: The confidence interval of the observed @entity204 rate excludes a dramatic decrease in mortality. No measurable effect was observed on the progression of detachment or on the speed of reepidermalization. These results do not support the routine use of IVIG treatment for @entity1 with @entity6715 or @entity137 , especially in cases of @entity8 .
